TNDM - Tandem Diabetes Care, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
47.84
+2.30 (+7.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close44.53
Open45.54
Bid0.00 x 3100
Ask0.00 x 900
Day's Range45.16 - 48.96
52 Week Range2.14 - 52.55
Volume6,187,159
Avg. Volume3,305,659
Market Cap2.738B
Beta-0.43
PE Ratio (TTM)N/A
EPS (TTM)-5.10
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.90
Trade prices are not sourced from all markets
  • Business Wire19 hours ago

    Tandem Diabetes Care Increases 2018 Sales Guidance and Provides Estimated Third Quarter Sales Results

    Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced that it has increased its 2018 sales guidance to $150 million to $158 million, from $140 million to $148 million, following continued strong domestic sales in the third quarter and the recent launch of the t:slim X2™ Insulin Pump in select international markets. Sales, training and customer service outside of the United States are being provided by regional distribution partners, except in Canada. The t:slim X2 Insulin Pump is currently under review by Health Canada.

  • Options Traders Expect Huge Moves in Tandem Diabetes Care (TNDM) Stock
    Zacks8 days ago

    Options Traders Expect Huge Moves in Tandem Diabetes Care (TNDM) Stock

    Tandem Diabetes Care (TNDM) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Motley Fool8 days ago

    Why Nio, Mersana Therapeutics, and Tandem Diabetes Care Slumped Today

    Find out what took the energy out of these stocks.

  • Why Tandem Diabetes Care Stock Is Crashing Today
    Market Realist9 days ago

    Why Tandem Diabetes Care Stock Is Crashing Today

    Today, Tandem Diabetes Care (TNDM) stock continued the declining trend it began on September 14. Baird downgraded the stock recommendation from “buy” to “neutral.” On September 14, TNDM stock registered a decline of ~6.7% in pre-market trading and the stock was down ~7% during the day. None of the analysts recommend a “buy” for Tandem Diabetes Care.

  • Motley Fool9 days ago

    Why Tandem Diabetes Care Is Sinking Today

    Shares dropped by double digits on Monday. What's going on?

  • Benzinga12 days ago

    Once Again, Baird Predicts End To Tandem's 'Fantastic' Run

    Without pause, Tandem Diabetes Care Inc (NASDAQ: TNDM ) has surged 1,915 percent year-to-date. One sell-side analyst said Friday that the medical device manufacturer's valuation has peaked.  The Rating ...

  • ACCESSWIRE13 days ago

    Today's Research Reports on Trending Tickers: InspireMD and Tandem Diabetes Care

    NEW YORK, NY / ACCESSWIRE / September 13, 2018 / U.S. markets were mixed on Wednesday as technology shares declined, dragging the Nasdaq into the red. The Dow Jones Industrial Average climbed 0.11 percent ...

  • Business Wire14 days ago

    Tandem Diabetes Care to Webcast Investor & Analyst Day on September 25, 2018

    Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced it will host an Institutional Investor and Analyst Day from 8:30am to 1:00pm Pacific Time on Tuesday, September 25, 2018 in San Diego, California. The program will include presentations regarding the Company’s longer-term vision, product pipeline, and international expansion. In addition, presentations will be given by clinical and industry experts on the subject of automated insulin delivery (AID).

  • Tandem Diabetes Is Firing on All Cylinders
    InvestorPlace15 days ago

    Tandem Diabetes Is Firing on All Cylinders

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM) continues to float higher, even without any major news. The market easily absorbed the company’s $100 million equity offering which was underwritten in August 2018. Not only are those who bought that offering at $28.50 in the green, but longtime investors in TNDM stock believe that sales of Tandem’s new insulin pump in the United States will justify the stock’s strong run-up.Source: Apple

  • Tandem Diabetes Care: One of the Best Medtech Stocks in 2018
    Market Realist15 days ago

    Tandem Diabetes Care: One of the Best Medtech Stocks in 2018

    Tandem Diabetes Care (TNDM) has been one of the best-performing medical device companies in 2018 and has already reported a YoY (year-over-year) rise of 1,814.4% YTD (year-to-date). To know more about Tandem Diabetes Care, be sure to read Tandem Diabetes Care Continues Its Strong Performance in Q2 2018. On June 21, the FDA approved Tandem Diabetes Care’s t:slim X2 insulin pump with Basal-IQ technology, an automated insulin delivery system that can help reduce the frequency of hypoglycemic events in diabetes patients.

  • Bloomberg19 days ago

    Insulin-Pump Maker Tandem Marks ‘Rebirth’ on Way to 1,800% Rally

    Two years ago, Tandem Diabetes Care Inc.’s stock plummeted after a key health insurer favored a rival device, investors fretted about growing competition and analysts wrung their hands over the balance sheet. Tandem’s market value has ballooned to more than $2.5 billion from $26 million just this year in what Chief Financial Officer Leigh Vosseller describes as an “almost a rebirth” following the “roller-coaster ride” that was the past two years. Bullish Wall Street analysts have played leap-frog in a race to slap ever-higher price targets on the stock: the current high stands at $60 a share, compared with Thursday’s $44.22 closing price.

  • Wall Street Analysts Are Increasingly Bullish on TNDM Stock
    Market Realist23 days ago

    Wall Street Analysts Are Increasingly Bullish on TNDM Stock

    Tandem Diabetes Care (TNDM) has had a stellar 2018 so far. The stock has registered eye-watering gains of 1,700% year-to-date. Over the last month, the stock is up ~77%.

  • ACCESSWIRE26 days ago

    Today's Research Reports on Trending Tickers: Tandem Diabetes Care and DaVita

    NEW YORK, NY / ACCESSWIRE / August 31, 2018 / Wall Street retreated from records on Thursday, on news that U.S. President Donald Trump wants to move ahead with his plan to slap tariffs on $200 billion ...

  • Business Wire27 days ago

    Tandem Diabetes Care to Present at the Baird Global Healthcare Conference

    Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Baird 2018 Global Healthcare Conference in New York, NY. The link to the live webcast and archive will be accessible on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section. Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience.

  • ACCESSWIRE29 days ago

    Today's Research Reports on Trending Tickers: Tandem Diabetes Care and Align Technology

    NEW YORK, NY / ACCESSWIRE / August 28, 2018 / U.S. markets rose Monday, with the S&P 500 and Nasdaq finishing at new records for the second consecutive session, on news of the new trade agreement with ...

  • Benzingalast month

    Tandem Diabetes Care Positioned For 20-30% Growth, But Valuation Warrants Neutral Stance

    Medical device maker Tandem Diabetes Care Inc (NASDAQ: TNDM ) has high growth potential, but its upside could be limited by valuation, according to Bank of America Merrill Lynch. The Analyst Analyst Travis ...

  • Is the Options Market Predicting a Spike in Tandem Diabetes (TNDM) Stock?
    Zackslast month

    Is the Options Market Predicting a Spike in Tandem Diabetes (TNDM) Stock?

    Investors need to pay close attention Tandem Diabetes (TNDM) stock based on the movements in the options market lately.

  • ACCESSWIRElast month

    With Overhang Gone, BTCY Could Generate Triple Digit Returns for Shareholders

    Investors recently long EKSO have made 65% with more potential upside to come. Tandem Diabetes Care, Inc. (TNDM) has traded from $2 to $34/share this year, a gain of over 1700%. This is based on improving commercial success with their diabetes business and another FDA approval in the summer.

  • Business Wirelast month

    Tandem Diabetes Care Announces Commercial Launch of t:slim X2 Insulin Pump with Basal-IQ Technology in the United States

    Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, today announced its launch of the t:slim X2™ Insulin Pump with Basal-IQ™ Technology, a predictive low glucose suspend (PLGS) feature designed to help reduce the frequency and duration of low glucose events (hypoglycemia). It is integrated with the Dexcom G6® CGM System, which requires no fingersticks for calibration or diabetes treatment decisions.1,2 The Company has begun sending emails with update instructions to all in-warranty t:slim X2 users in the United States, who have the option to add the new feature free of charge via remote software update.3 t:slim X2 Pumps pre-loaded with Basal-IQ Technology are expected to begin shipping to new customers by the end of August.

  • 7 Cheap Stocks Under $7
    InvestorPlacelast month

    7 Cheap Stocks Under $7

    When it comes to investing, it’s definitely smart to focus on high-quality companies. But this does not mean you should avoid more speculative plays. Low-price, cheap stocks can represent tremendous opportunities.

  • What Does Tandem Diabetes Care’s Valuation Trend Indicate?
    Market Realist2 months ago

    What Does Tandem Diabetes Care’s Valuation Trend Indicate?

    From $8.80 on May 8, Tandem Diabetes Care’s (TNDM) stock price steadily rose to a high of $33.44 on August 3. It recovered after that to its current level of $30.75.

  • Exploring Tandem Diabetes Care’s Product Pipeline
    Market Realist2 months ago

    Exploring Tandem Diabetes Care’s Product Pipeline

    Additionally, Tandem commenced enrollment in the US portion of the International Diabetes closed Loop trial in June. Tandem is developing a next-generation hardware platform, t:sport Insulin Delivery System, which is expected to be half the size of the t:slim pump.

  • Understanding Tandem Diabetes Care’s Recent Stock Offerings
    Market Realist2 months ago

    Understanding Tandem Diabetes Care’s Recent Stock Offerings

    Tandem Diabetes Care’s (TNDM) interest expenses increased from $2.89 million in the second quarter of 2017 to $3.11 million in the second quarter. Its net other expense jumped from $2.83 million in the second quarter of 2017 to $45.36 million in the second quarter primarily due to a revaluation loss of $42.55 million in the fair value of Tandem’s Series A and Series B stock warrants.

  • Tandem Diabetes Care’s Top Line Grows 60% in Q2 2018
    Market Realist2 months ago

    Tandem Diabetes Care’s Top Line Grows 60% in Q2 2018

    Tandem Diabetes Care (TNDM) generated revenues of ~$34.13 million in the second quarter, which it reported on July 30. It reported revenues of $21.33 million in the second quarter of 2017. 

  • The three stocks options traders say could move
    CNBC Videos29 days ago

    The three stocks options traders say could move

    Options action may be signalling a move